Risk factors influencing mortality related to Stenotrophomonas maltophilia infection in hematology-oncology patients

被引:25
作者
Demiraslan, Hayati [1 ]
Sevim, Mustafa [2 ]
Pala, Cigdem [3 ]
Durmaz, Suleyman [4 ]
Berk, Veli [5 ]
Kaynar, Leylagul [3 ]
Metan, Gokhan [1 ]
机构
[1] Erciyes Univ, Fac Med, Dept Infect Dis & Clin Microbiol, Kayseri, Turkey
[2] Erciyes Univ, Fac Med, Dept Internal Med, Kayseri, Turkey
[3] Erciyes Univ, Fac Med, Dept Hematol, Kayseri, Turkey
[4] Erciyes Univ, Fac Med, Dept Microbiol, Kayseri, Turkey
[5] Erciyes Univ, Fac Med, Dept Oncol, Kayseri, Turkey
关键词
Stenotrophomonas maltophilia; Hematologic malignancy; Solid tumor; Cancer; Severe sepsis; Neutropenia; Mortality; ANTIMICROBIAL SURVEILLANCE PROGRAM; CENTRAL VENOUS CATHETER; BACTEREMIA; DEFINITIONS; THERAPY; GUIDELINES; MANAGEMENT; RESISTANCE; PATHOGEN; PATTERNS;
D O I
10.1007/s12185-013-1296-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Stenotrophomonas maltophilia infection is of concern in patients with cancer. Antibiotics active against S. maltophilia are rarely used in the treatment of febrile neutropenia, making it important to identify the factors influencing mortality in cancer patients with S. maltophilia infection. The objective of this study was to analyze the clinical characteristics and outcomes of cancer and hemopathic patients with S. maltophilia infection and assess the factors influencing the mortality. The microbiology laboratory records of Erciyes University, Faculty of Medicine Hospital were reviewed to retrospectively identify patients with S. maltophilia infection between January 2007 and June 2011. A total of 38 patients (25 male, 13 female) were eligible for the study. The median age of the patients was 53 years. The underlying disease was hematological malignancy and disorders in 76.3 % (29 cases), solid tumors in 15.8 % (six cases), aplastic anemia in 7.9 % (three cases), while 18.4 % (seven cases) were hematopoietic stem cell transplantation (HSCT) recipients. An indwelling central venous catheter was used in 32 cases (84.2 %). Twenty-seven patients (71.1 %) were neutropenic at the onset of infection. Nine patients (23.7 %) were receiving corticosteroid therapy. The overall 14-day mortality rate was 50 %. Three of the patients received empirical antibacterial treatment, and three HSCT recipients received trimethoprim-sulfamethoxazole prophylaxis, which is active against S. maltophilia. Severe sepsis (OR 13.24, 95 % confidence interval (CI) 1.62-108.57) and the duration of the treatment (OR 0.73, 95 % CI 0.60-0.90) were related to death based on logistic regression analysis findings. In immunocompromised hematology-oncology patients with severe sepsis, S. maltophilia should be considered as a possible cause of infection, and should be given effective empirical antibiotic treatment immediately; the antimicrobial spectrum may be narrowed according to results of antibiotic susceptibility test.
引用
收藏
页码:414 / 420
页数:7
相关论文
共 50 条
[31]   Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients [J].
Waters, Valerie ;
Atenafu, Eshetu G. ;
Lu, Annie ;
Yau, Yvonne ;
Tullis, Elizabeth ;
Ratjen, Felix .
JOURNAL OF CYSTIC FIBROSIS, 2013, 12 (05) :482-486
[32]   Case series: Stenotrophomonas maltophilia in pediatric oncology patients [J].
Sarkar, Sanila ;
Stitzlein, Lea M. ;
Rav, Emily ;
Garcia, Miriam B. ;
Razvi, Shehla ;
Chang, Michael ;
Zakhour, Ramia .
CANCER REPORTS, 2024, 7 (03)
[33]   Stenotrophomonas maltophilia Infections: Clinical Characteristics and Factors Associated with Mortality of Hospitalized Patients [J].
Insuwanno, Worachart ;
Kiratisin, Pattarachai ;
Jitmuang, Anupop .
INFECTION AND DRUG RESISTANCE, 2020, 13 :1559-1566
[34]   Infection Probability Score, APACHE II and KARNOFSKY scoring systems as predictors of bloodstream infection onset in hematology-oncology patients [J].
Apostolopoulou, Eleni ;
Raftopoulos, Vasilios ;
Terzis, Konstantinos ;
Elefsiniotis, Ioannis .
BMC INFECTIOUS DISEASES, 2010, 10
[35]   Evaluation of Inflammatory Biomarkers in Pediatric Hematology-Oncology Patients With Bloodstream Infection [J].
Chen, Senmin ;
Liu, Sixi ;
Yuan, Xiuli ;
Wang, Huihui ;
Wen, Feiqiu .
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2021, 43 (04) :E596-E600
[36]   Risk factors for mortality in patients with Stenotrophomonas maltophilia bacteremia and clinical impact of quinolone–resistant strains [J].
Eun Jin Kim ;
Yong Chan Kim ;
Jin Young Ahn ;
Su Jin Jeong ;
Nam Su Ku ;
Jun Yong Choi ;
Joon-Sup Yeom ;
Young Goo Song .
BMC Infectious Diseases, 19
[37]   Levofloxacin-resistant Stenotrophomonas maltophilia: risk factors and antibiotic susceptibility patterns in hospitalized patients [J].
Wang, C. H. ;
Yu, C-M ;
Hsu, S-T ;
Wu, R-X .
JOURNAL OF HOSPITAL INFECTION, 2020, 104 (01) :46-52
[38]   Risk factors for mortality in intensive care unit patients with Stenotrophomonas maltophilia pneumonia in South Korea [J].
Lee, Yong Hoon ;
Lee, Jaehee ;
Yu, Byunghyuk ;
Lee, Won Kee ;
Choi, Sun Ha ;
Park, Ji Eun ;
Seo, Hyewon ;
Yoo, Seung Soo ;
Lee, Shin Yup ;
Cha, Seung-Ick ;
Kim, Chang Ho ;
Park, Jae Yong .
ACUTE AND CRITICAL CARE, 2023, 38 (04) :442-451
[39]   Stenotrophomonas maltophilia pneumonia in cancer patients without traditional risk factors for infection, 1997–2004 [J].
G. Aisenberg ;
K. V. Rolston ;
B. F. Dickey ;
D. P. Kontoyiannis ;
I. I. Raad ;
A. Safdar .
European Journal of Clinical Microbiology & Infectious Diseases, 2007, 26
[40]   Risk factors for mortality among patients with Stenotrophomonas maltophilia bacteremia in Tokyo, Japan, 1996-2009 [J].
Araoka, H. ;
Baba, M. ;
Yoneyama, A. .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2010, 29 (05) :605-608